Abington Neurological Associates’ Dr. David Weisman sat down with NBC10’s Keith Jones to discuss the effects of Alzheimer’s Disease and the NOBLE clinical trial.
It’s a slow disease, and it’s one that doesn’t have a lot of what we call biomarkers. So, for instance, cancer: you take a few people with cancer, and if you have a medication that shrinks the tumors on scans, then you can scale that up easily. Alzheimer’s is much harder and it’s much slower. It’s such a slow disease that we need dozens and hundreds of people over many years to see an effect. You can’t scale it up easily.
Watch the full interview on nbcphiladelphia.com.